Table 1 |
||||
|
Baseline characteristics of the intention-to-treat (ITT) population with osteoarthritis of the knee |
||||
|
Risedronate |
||||
|
|
||||
|
Characteristic |
Placebo (n = 98) |
5 mg/day (n = 96) |
15 mg/day (n = 90) |
P |
|
|
||||
|
Age (years) |
63.2 (0.82) |
62.9 (0.90) |
63.8 (0.88) |
0.652a |
|
Height (cm) |
164.3 (0.90) |
165.3 (0.97) |
165.1 (0.93) |
0.614a |
|
Body mass index (kg/m2) |
29.2 (0.38) |
29.0 (0.40) |
29.2 (0.42) |
0.799a |
|
Sex (no. (%)) |
0.307b |
|||
|
Male |
34 (35%) |
40 (42%) |
41 (46%) |
|
|
Female |
64 (65%) |
56 (58%) |
49 (54%) |
|
|
Post-menopausal (no. (%)) |
54 (84%) |
49 (88%) |
43 (88%) |
0.985b |
|
Years since menopause |
14.4 (1.22) |
16.5 (1.57) |
17.4 (1.42) |
0.273a |
|
Oestrogen or SERM use (no. (%)) |
18 (28%) |
15 (27%) |
10 (20%) |
0.380b |
|
Race (no.) |
0.385b |
|||
|
Asian Oriental |
1 |
0 |
0 |
|
|
Asian Indian |
1 |
0 |
2 |
|
|
Caucasian |
96 |
96 |
88 |
|
|
Joint-space width (mm) |
3.03 (0.05) |
2.95 (0.05) |
3.01 (0.06) |
0.577a |
|
WOMAC – weighted total score |
50.3 (2.0) |
46.1 (2.0) |
49.4 (2.4) |
0.281a |
|
Use of walking aids (no. (%)) |
16 (16) |
22 (23) |
12 (13) |
0.224b |
|
uCTX-II (ng/mmol creatinine) |
312.5 (19.9) |
328.9 (29.7) |
340.1 (24.0) |
0.748a |
|
uNTX-I (nmol/mmol creatinine) |
40.3 (2.8) |
42.3 (4.5) |
38.6 (2.2) |
0.954a |
|
|
||||
|
Unless indicated otherwise, values are means (standard errors of the mean). aKruskal–Wallis test; bFisher exact test. SERM, selective oestrogen receptor modulator; uCTX-II, urinary C-terminal crosslinking telopeptide of type II collagen; uNTX-I, urinary N-terminal crosslinking telopeptide of type I collagen; WOMAC, Western Ontario and McMaster Universities osteoarthritis index. |
||||
|
Spector et al. Arthritis Research & Therapy 2005 7:R625 doi:10.1186/ar1716 |
||||
